HPGC(SH:600664)2023-04-27 16:00Financial Performance - The company's operating revenue for Q1 2023 was CNY 3,931,549,972.98, representing a year-on-year increase of 17.93%[4] - The net profit attributable to shareholders for Q1 2023 was CNY 122,293,236.02, up 21.75% compared to the same period last year[4] - Basic earnings per share for Q1 2023 were CNY 0.05, an increase of 25.00% from the previous year[4] - Total operating revenue for Q1 2023 reached ¥3,931,549,972.98, a 17.9% increase from ¥3,333,837,987.01 in Q1 2022[16] - Net profit for Q1 2023 was ¥139,987,574.96, representing a 27.4% increase compared to ¥109,934,338.19 in Q1 2022[17] - Total comprehensive income for Q1 2023 was ¥141,147,470.62, compared to ¥110,203,928.60 in Q1 2022, reflecting a growth of 28.1%[18] Cash Flow - The net cash flow from operating activities was CNY 182,625,091.63, reflecting a 17.91% increase year-on-year[4] - Cash inflow from operating activities in Q1 2023 was ¥4,022,411,651.90, up 22.7% from ¥3,277,424,882.21 in Q1 2022[20] - Net cash flow from operating activities for Q1 2023 was 182,625,091.63, an increase from 154,882,854.26 in Q1 2022, representing a growth of approximately 17.5%[21] - Net cash flow from financing activities was 62,865,637.35, a significant improvement from -5,098,076.67 in Q1 2022[22] - The company reported a net increase in cash and cash equivalents of 231,223,678.32, compared to 161,605,207.78 in the same period last year, representing a growth of approximately 43.0%[22] Assets and Liabilities - Total assets at the end of Q1 2023 were CNY 13,540,956,681.83, a 0.78% increase from the end of the previous year[4] - The company's total assets amounted to RMB 13,540,956,681.83, an increase from RMB 13,435,980,913.62 as of December 31, 2022, reflecting a growth of approximately 0.78%[15] - The company's total liabilities were RMB 8,447,947,901.95, down from RMB 8,484,927,244.36, representing a decrease of about 0.44%[14] - The company’s total liabilities to equity ratio improved to approximately 1.67 from 1.71, indicating a stronger equity position relative to liabilities[14] Expenses - The company's R&D expenses increased by 34.49% year-on-year, attributed to the expansion of R&D projects[6] - The company reported a 44.87% increase in sales expenses, driven by higher investment in health product business due to increased revenue[6] - Total operating costs for Q1 2023 were ¥3,749,463,341.18, up 18.0% from ¥3,175,613,101.54 in Q1 2022[16] - The company reported a decrease in financial expenses to ¥8,332,222.00 in Q1 2023 from ¥28,262,561.51 in Q1 2022[16] Shareholder Equity - The company's equity attributable to shareholders increased to RMB 4,455,333,420.22 from RMB 4,331,072,648.54, reflecting a growth of approximately 2.86%[14] - The company completed the repurchase and cancellation of 2,399,000 restricted stocks as part of its stock incentive plan, reducing total shares from 2,525,877,076 to 2,523,478,076[9]